RecruitingNot ApplicableNCT07048002

Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery

Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)


Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Enrollment

912 participants

Start Date

Jul 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy. The NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass. The primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery? To address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.


Eligibility

Min Age: 60 Years

Inclusion Criteria3

  • Male or female adult patients aged 60 years or older
  • Receiving elective cardiovascular surgery with cardiopulmonary bypass
  • Written Informed consent provided

Exclusion Criteria7

  • Contraindication to MRI scanning
  • Not suitable for receiving interventions to achieve NeuroFirst target bundle
  • Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments
  • Breastfeeding or pregnancy
  • Terminal illness with a life expectancy of less than 3 months
  • Mental or legal disability
  • current enrollment in other interventional study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERManagements for NeuroFirst target bundle

In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% , and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB. To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments.

OTHERManagements for institutional routine

MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.


Locations(5)

Beijing Chaoyang Hospital,Capital Medical University

Beijing, Beijing Municipality, China

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College

Beijing, Beijing Municipality, China

Xuanwu Hospital,Capital Medical University

Beijing, Beijing Municipality, China

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07048002


Related Trials